2023-10-27 16:00Financial Performance - Q3 2023 revenue reached ¥316,754,900.60, an increase of 16.31% year-over-year[4] - Net profit attributable to shareholders was -¥409,405,996.25, with a year-to-date loss of -¥1,406,818,402.73[4] - Basic and diluted earnings per share for the quarter were both -¥0.42, compared to -¥1.43 year-to-date[5] - Total revenue for the first three quarters of 2023 was ¥986,457,567.67, a decrease of 19.06% compared to ¥1,218,381,861.73 in the same period of 2022[15] - Net loss for the third quarter of 2023 was ¥1,555,128,891.35, compared to a net loss of ¥1,734,538,953.68 in the same quarter of 2022, showing an improvement[17] - The company reported a basic and diluted earnings per share of -¥1.43 for the third quarter of 2023, an improvement from -¥1.75 in the same quarter of 2022[18] Research and Development - Total R&D investment for the quarter was ¥322,027,822.49, a decrease of 43.89% year-over-year, representing 101.66% of revenue[5] - Research and development expenses for the first three quarters of 2023 amounted to ¥1,270,626,649.07, a decrease of 22.36% compared to ¥1,636,118,643.63 in 2022[15] - The company is advancing clinical trials for its first-in-human anti-tumor antibody, Tifcemalimab, in combination with Toripalimab for small cell lung cancer[12] - The company has received approval for the clinical trial application of a PD-1 and VEGF bispecific antibody, with the first patient dosing completed[12] Assets and Liabilities - Total assets at the end of the quarter were ¥11,587,144,221.39, down 7.73% from the end of the previous year[5] - The company's total equity decreased to ¥8,337,698,673.95 in 2023 from ¥9,776,460,263.22 in 2022, a decline of 14.73%[15] - Total liabilities increased to ¥3,249,445,547.44 in 2023 from ¥2,782,035,912.21 in 2022, reflecting a growth of 16.83%[15] - The company reported cash and cash equivalents of approximately RMB 4.17 billion as of September 30, 2023, down from RMB 6.03 billion at the end of 2022[14] - The total assets of the company decreased to approximately RMB 11.59 billion as of September 30, 2023, compared to RMB 12.56 billion at the end of 2022[14] Shareholder Information - The company had 32,991 common shareholders at the end of the reporting period[8] - The largest shareholder, HKSCC NOMINEES LIMITED, held 22.25% of shares, totaling 219,291,230 shares[8] Cash Flow - The company reported a net cash outflow from operating activities of -¥1,664,114,192.65 year-to-date[4] - The total cash inflow from operating activities was 1,236,480,347.79, while total cash outflow was 2,900,594,540.44, reflecting a challenging operational environment[19] - Cash inflow from financing activities amounted to 937,789,838.50, with cash outflow of 496,595,535.82, leading to a net cash flow from financing activities of 441,194,302.68[19] - The ending balance of cash and cash equivalents was 4,141,718,242.77, compared to 3,001,414,742.11 at the end of the previous year, showing an increase in liquidity[20] - The company experienced a foreign exchange impact on cash and cash equivalents amounting to 21,536,381.05, which affected the overall cash position[19] Sales Performance - Sales revenue from the drug Toripalimab (brand name: Tuoyi®) reached approximately RMB 668 million, an increase of about 29.7% year-on-year[12] - The company achieved a total revenue of approximately RMB 892 million for the year-to-date, representing a year-on-year growth of approximately 67.8%[12] Inventory and Receivables - The company reported accounts receivable of approximately RMB 366 million as of September 30, 2023, up from RMB 238 million at the end of 2022[14] - Inventory increased to approximately RMB 748 million as of September 30, 2023, compared to RMB 599 million at the end of 2022[14]